KIAA1199 Inhibitors
KIAA1199 inhibitors encompass a variety of chemical entities that target signaling pathways and cellular processes directly involved in the functional regulation of KIAA1199, primarily associated with cell migration. The inhibition mechanisms of these chemicals are multifaceted, often involving the disruption of kinase activities that are central to migration signaling cascades. For instance, compounds that inhibit tyrosine kinases can lead to a decrease in cellular processes where KIAA1199 is a key player, thereby reducing its functional activity. Similarly, the targeting of phosphoinositide 3-kinases (PI3Ks) and mitogen-activated protein kinase kinases (MEK1/2) through specific inhibitors can suppress the PI3K/Akt and MAPK/ERK pathways, respectively. These pathways are integral to cell survival, motility, and migration, thereby indirectly modulating the activity of KIAA1199. The use of inhibitors that block p38 MAPK also affects the cellular response to stress and inflammation, processes in which the role of KIAA1199 is implicated due to its involvement in cell migration.
Additionally, inhibitors that attenuate the function of c-Jun N-terminal kinase (JNK) can hamper cytoskeletal reorganization and cellular movement, which are essential for the migration-related activity of KIAA1199. Inhibition of the Rho/MRTF/SRF transcriptional pathway, essential for cytoskeletal dynamics, also serves to disrupt KIAA1199's role in promoting cell migration. Small molecules such as ROCK inhibitors, which impact cell shape and motility by targeting the actin cytoskeleton, can further influence the function of KIAA1199. The blockade of other key proteins like Rac1, a GTPase involved in actin organization, and myosin II, critical for cell contractility, also contributes to the indirect inhibition of KIAA1199's migration-facilitating activities. Moreover, the inhibition of AMP-activated protein kinase (AMPK), a regulator of cell polarity and migration, is another avenue by which the activity of KIAA1199 can be influenced.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $45.00 $164.00 $200.00 $402.00 $575.00 $981.00 $2031.00 | 46 | |
Genistein is an isoflavone that acts as a tyrosine kinase inhibitor. By inhibiting tyrosine kinase activity, it can affect cellular processes such as proliferation and migration, in which KIAA1199 is implicated. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY 294002 is a specific inhibitor of phosphoinositide 3-kinases (PI3Ks). PI3K signaling is crucial for various cellular functions including migration. Inhibition of PI3K can disrupt processes involving KIAA1199. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is an inhibitor of mitogen-activated protein kinase kinases (MEK1/2), blocking the MAPK/ERK pathway. This pathway is involved in cell migration, where KIAA1199 also plays a role. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB 203580 is a p38 MAPK inhibitor which affects the cellular response to stress and inflammation. As KIAA1199 is associated with cell migration, inhibiting p38 MAPK can disrupt KIAA1199-mediated processes. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent PI3K inhibitor. It blocks the PI3K/Akt signaling pathway, which is involved in cell survival and migration, thereby potentially affecting the function of KIAA1199 in these processes. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), impacting cell movement and cytoskeletal reorganization. By inhibiting JNK, the migration-related activity of KIAA1199 could be indirectly inhibited. | ||||||
CCG-1423 | 285986-88-1 | sc-205241 sc-205241A | 1 mg 5 mg | $30.00 $90.00 | 8 | |
CCG-1423 inhibits the Rho/MRTF/SRF transcriptional pathway, which is involved in cytoskeletal dynamics and cell migration. This inhibition could also affect the migration-promoting activity of KIAA1199. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Y-27632 is a ROCK inhibitor that influences cell shape and motility by acting on the actin cytoskeleton. Inhibiting ROCK can thus affect KIAA1199's role in cell migration. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD 98059 is a MEK inhibitor that blocks the MAPK/ERK pathway, which has implications for cell motility and migration. By inhibiting this pathway, KIAA1199's associated activities could be affected. | ||||||
(±)-Blebbistatin | 674289-55-5 | sc-203532B sc-203532 sc-203532A sc-203532C sc-203532D | 5 mg 10 mg 25 mg 50 mg 100 mg | $183.00 $313.00 $464.00 $942.00 $1723.00 | 7 | |
An inhibitor of myosin II ATPase activity, affecting cell contractility and motility. By inhibiting myosin II, the migration and invasion processes involving KIAA1199 can be indirectly impaired. | ||||||